Inhaled Pentamidine for PCP Prophylaxis
For Pneumocystis jirovecii pneumonia (PCP) prophylaxis, administer 300 mg of pentamidine isethionate via Respirgard II nebulizer once monthly, diluted in 6 mL sterile water and delivered at 6 L/min airflow until the reservoir is dry. 1
Dosing Regimens
Two validated delivery systems exist with different schedules:
Respirgard II Jet Nebulizer (Preferred for Simplicity)
- Dose: 300 mg pentamidine isethionate once every 4 weeks
- Preparation: Dilute in 6 mL sterile water
- Delivery: Air flow of 6 L/min from 50-PSI compressed air source until reservoir is dry
- Effective for: Both primary and secondary prophylaxis 1
Fisoneb Ultrasonic Nebulizer (Alternative)
- Loading phase: 60 mg pentamidine in 3 mL sterile water, five doses spaced 24-72 hours apart over first 2 weeks
- Maintenance: 60 mg every 2 weeks thereafter
- Duration: Inhale 15-20 minutes until reservoir is dry 1
Important caveat: The Fisoneb device is not FDA-approved and may not be currently available in the United States 1
Indications for Prophylaxis
Primary Prophylaxis
- CD4+ T-cell count <200 cells/µL
- Constitutional symptoms (thrush or unexplained fever >100°F for ≥2 weeks) regardless of CD4+ count
- Continue for patient's lifetime 1
Secondary Prophylaxis
- Any patient who has recovered from documented PCP episode 1
Pre-Treatment Requirements
Before initiating aerosol pentamidine, mandatory screening includes:
- Medical history for tuberculosis
- Tuberculin skin test
- Chest radiograph
- If cough or pulmonary infiltrate present: acid-fast bacilli smears and cultures of sputum 1
This is critical because aerosol pentamidine can mask or complicate tuberculosis diagnosis and poses transmission risks to healthcare workers.
Managing Bronchospasm
Pretreatment protocol for patients who develop cough, wheezing, or chest pain:
- Administer inhaled beta-2 agonist (e.g., albuterol 2 puffs, 100 µg each) immediately
- Pretreat 10 minutes before each subsequent pentamidine administration 1
This is a common issue—coughing occurs in approximately 36% and wheezing in 11% of patients, though only 5.6% discontinue therapy 1
Efficacy Considerations
TMP-SMX remains superior to aerosol pentamidine in terms of efficacy and cost 1. The 1-year PCP recurrence rate with aerosol pentamidine is 18.5% versus 3.5% with TMP-SMX (3.25-fold higher risk) 1. However, aerosol pentamidine is the recommended alternative when TMP-SMX cannot be tolerated due to rash, cytopenias, or transaminase elevations 1.
Recent data suggests 300 mg every 4 weeks is 60-70% effective for primary prevention 2, with approximately 53 inhalations needed to prevent one PCP episode. Some evidence supports 300 mg every 2 weeks for potentially improved efficacy 3, though this requires further validation.
Safety and Infection Control
Critical infection control measures:
- Administer in individual rooms/booths with negative-pressure ventilation
- Exhaust air directly outside, away from windows and air-intake ducts
- Healthcare workers must wear particulate respirators when in room during administration if patient has or is at high risk for tuberculosis
- Patients should not return to common waiting areas until coughing subsides
- Allow adequate time for air clearance before next patient use 1
Limitations
- Not effective for patients with severe pulmonary function abnormalities (efficacy and safety not established) 1
- Patients developing PCP while on aerosol pentamidine may present with atypical features (especially upper-lobe infiltrates) and diagnosis may be more difficult 1, 4
- Does not provide systemic protection against extrapulmonary pneumocystosis 4
Alternative: Intravenous Pentamidine
During respiratory virus pandemics (e.g., COVID-19) when aerosolized medications pose contamination risks, IV pentamidine 4 mg/kg (maximum 300 mg) monthly is an effective and well-tolerated alternative 5, 6. Recent prospective data shows no breakthrough PCP infections and high patient satisfaction (86%) with this route 6.